OrthoPediatrics Corp. (KIDS)
NASDAQ: KIDS
· Real-Time Price · USD
22.81
-0.40 (-1.72%)
At close: May 14, 2025, 2:27 PM
OrthoPediatrics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|
| ACL Reconstruction and Other Revenue | 4.45M | 4.02M | 3.81M | 4.17M | 2.66M | 1.7M | 1.2M | 1.23M |
| ACL Reconstruction and Other Revenue Growth | +10.70% | +5.57% | -8.82% | +56.74% | +57.02% | +41.10% | -2.59% | n/a |
| Spine Revenue | 55.15M | 37.93M | 33.43M | 28.05M | 20.74M | 21.48M | 16.66M | 11.59M |
| Spine Revenue Growth | +45.40% | +13.48% | +19.19% | +35.24% | -3.48% | +28.95% | +43.82% | n/a |
| Trauma and Deformity Revenue | 145.13M | 106.78M | 85.06M | 65.83M | 47.68M | 49.37M | 39.7M | 32.8M |
| Trauma and Deformity Revenue Growth | +35.91% | +25.54% | +29.21% | +38.07% | -3.43% | +24.38% | +21.02% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 46.85M | 41.22M | 43.05M | 39.14M | 33.87M | 26.55M | 32.09M | 32.82M | 29.88M | 27.5M | 27.04M | 26.98M | 22.93M | 22.03M | 20.9M | 21.96M | 20.99M | 19.47M | 19.06M | 16.2M | 15.45M | 15.58M | 16.04M | 14.18M | 12.16M | 11.1M | 12.03M | 12.28M | 12.1M | 12.1M | 9.12M | 8.72M | 7.57M | 9.03M | 7.18M | 7.1M | 6.96M | 5.78M |
| Selling, General, and Administrative Revenue Growth | +13.68% | -4.26% | +9.98% | +15.56% | +27.56% | -17.25% | -2.22% | +9.83% | +8.67% | +1.72% | +0.21% | +17.68% | +4.04% | +5.45% | -4.86% | +4.64% | +7.81% | +2.15% | +17.68% | +4.87% | -0.84% | -2.88% | +13.14% | +16.58% | +9.51% | -7.68% | -2.02% | +1.48% | +0.01% | +32.62% | +4.58% | +15.28% | -16.21% | +25.76% | +1.08% | +2.00% | +20.49% | n/a |
| Research and Development Revenue | 2.35M | 2.92M | 2.58M | 2.54M | 3M | 2.75M | 2.39M | 2.79M | 2.27M | 2.03M | 2.21M | 1.75M | 2.03M | 1.61M | 1.3M | 1.32M | 1.31M | 2.05M | 1.08M | 881K | 1.26M | 1.91M | 1.4M | 1.23M | 1.21M | 1.28M | 1.12M | 1.11M | 1.22M | 941K | 1.13M | 668K | 687K | 624K | 501K | 589K | 507K | 479K |
| Research and Development Revenue Growth | -19.38% | +13.15% | +1.34% | -15.18% | +9.14% | +15.08% | -14.51% | +23.00% | +11.60% | -7.80% | +26.27% | -13.81% | +26.06% | +23.50% | -1.74% | +1.30% | -36.20% | +90.34% | +22.25% | -30.36% | -33.60% | +36.46% | +13.13% | +1.73% | -5.01% | +13.81% | +0.63% | -8.46% | +29.44% | -16.50% | +68.71% | -2.77% | +10.10% | +24.55% | -14.94% | +16.17% | +5.85% | n/a |
| Sales and Marketing Revenue | 16.57M | 16.78M | 16.75M | 16.59M | 14.17M | 12.44M | 13.58M | 13.16M | 12.22M | 10.95M | 11.92M | 12.43M | 9.76M | 9.99M | 9.86M | 10.88M | 8.95M | 9.43M | 9.24M | 5.62M | 7.56M | 8.36M | 8.77M | 7.61M | 6.55M | 6.56M | 7.15M | 6.78M | 6.08M | 5.41M | 5.63M | 5.3M | 4.19M | 4.26M | 4.29M | 4.34M | 3.77M | 3.21M |
| Sales and Marketing Revenue Growth | -1.26% | +0.20% | +0.95% | +17.11% | +13.91% | -8.42% | +3.17% | +7.77% | +11.61% | -8.17% | -4.12% | +27.39% | -2.28% | +1.26% | -9.32% | +21.53% | -5.13% | +2.12% | +64.36% | -25.70% | -9.52% | -4.69% | +15.32% | +16.18% | -0.17% | -8.28% | +5.52% | +11.47% | +12.47% | -4.05% | +6.30% | +26.41% | -1.60% | -0.68% | -1.08% | +15.01% | +17.56% | n/a |